Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Sanofi, after R&D setback, lends a hand to vaccine rival Pfizer for coronavirus shot production
Johnson & Johnson's closely watched single-shot COVID-19 vaccine readout 'next week' as CFO sees 'robust data'
Here's how the NFL tackled the spread of COVID-19 among players, staff
Regeneron pitches COVID-19 antibody cocktail for 'passive vaccination' with fresh trial data
Lilly antibody combo slashed COVID-19 deaths, hospitalizations in high-risk patients
Kaufman Hall: Hospitals close out 2020 with declining margins and higher expenses due to COVID-19
Johnson & Johnson is 'comfortable' meeting coronavirus vaccine delivery promises, CFO says
Abbott's Panbio antigen test obtains new European approvals for mass COVID-19 screening
Healthcare roundup: Lyft urges CMS to consider transportation challenges to vaccine sites
Emergent BioSolutions unveils 7th pandemic CDMO contract, this time for Humanigen's late-stage antibody hopeful

Featured Story

Sanofi, after R&D setback, lends a hand to vaccine rival Pfizer for coronavirus shot production

By Eric Sagonowsky

Following its midstage coronavirus R&D setback, vaccine giant Sanofi is still looking for ways to help in the world’s effort to beat back the pandemic. It’s teaming up with leading vaccine players Pfizer and BioNTech to produce 100 million doses of the rival vaccine—even as Sanofi works to push its own programs through clinical testing.

Johnson & Johnson's closely watched single-shot COVID-19 vaccine readout 'next week' as CFO sees 'robust data'

By Ben Adams

While the world struggles with two-shot vaccine production as a handful of pharma companies try to make enough for almost the entire global population, a single-dose option from Johnson & Johnson has become a major hope in the fight against COVID-19.

Here's how the NFL tackled the spread of COVID-19 among players, staff

By Heather Landi

During a global pandemic, the NFL got all 256 regular-season games played within 17 weeks in 2020. Despite the close physical contact among players on the field, the NFL was able to reduce the spread of the virus. Here are lessons learned from the league's mitigation strategies that can be applied to workplaces and schools.

Regeneron pitches COVID-19 antibody cocktail for 'passive vaccination' with fresh trial data

By Arlene Weintraub

A preliminary readout from a phase 3 trial of Regeneron's antibody cocktail showed the drug halved the rate of infection and prevented symptoms completely in people at high risk of contracting COVID-19. The cocktail could offer an alternative to vaccines, which are in short supply, the company argued.

Lilly antibody combo slashed COVID-19 deaths, hospitalizations in high-risk patients

By Eric Sagonowsky

Amid new worries about COVID-19 vaccine supplies, monoclonal antibodies—such as those from Eli Lilly and Regeneron—could be important stopgaps to reduce deaths and hospitalizations until vaccinations gain steam. And Lilly is touting data showing two of its antibodies did just that in high-risk patients.

Kaufman Hall: Hospitals close out 2020 with declining margins and higher expenses due to COVID-19

By Robert King

The hospital industry closed out 2020 with declines in financial performance due to the pandemic, according to a new report from Kaufman Hall that doesn't believe things will get immediately better for hospitals in 2021.

Johnson & Johnson is 'comfortable' meeting coronavirus vaccine delivery promises, CFO says

By Eric Sagonowsky

As the world awaits J&J's phase 3 COVID-19 vaccine data, the company is prepping for regulatory filings and global rollouts. Orders for hundreds of millions of doses are pending. But at a time when rivals face manufacturing and logistics hurdles, a top exec said J&J can comfortably meet its 2021 supply commitments.

Abbott's Panbio antigen test obtains new European approvals for mass COVID-19 screening

By Conor Hale

Abbott has received new COVID-19 diagnostic approvals in Europe for its rapid Panbio antigen test, clearing it for self-performed screening under supervision, as well as widespread use by people who have not shown symptoms of the disease.

Healthcare roundup: Lyft urges CMS to consider transportation challenges to vaccine sites

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Emergent BioSolutions unveils 7th pandemic CDMO contract, this time for Humanigen's late-stage antibody hopeful

By Fraiser Kansteiner

Manufacturing powerhouse Emergent BioSolutions unveiled its seventh COVID-19 CDMO tie-up Monday, this time to help crank out Humanigen’s late-stage antibody hopeful lenzilumab. Emergent will hustle along fill-finish work on lenzilumab at its Camden plant in Baltimore, boosting supplies ahead of a possible emergency nod early this year.

COVID-19 Tracker

Featured Story

Sanofi, after R&D setback, lends a hand to vaccine rival Pfizer for coronavirus shot production

Top Stories

Johnson & Johnson's closely watched single-shot COVID-19 vaccine readout 'next week' as CFO sees 'robust data'

Here's how the NFL tackled the spread of COVID-19 among players, staff

Regeneron pitches COVID-19 antibody cocktail for 'passive vaccination' with fresh trial data

Lilly antibody combo slashed COVID-19 deaths, hospitalizations in high-risk patients

Kaufman Hall: Hospitals close out 2020 with declining margins and higher expenses due to COVID-19

Johnson & Johnson is 'comfortable' meeting coronavirus vaccine delivery promises, CFO says

Abbott's Panbio antigen test obtains new European approvals for mass COVID-19 screening

Healthcare roundup: Lyft urges CMS to consider transportation challenges to vaccine sites

Emergent BioSolutions unveils 7th pandemic CDMO contract, this time for Humanigen's late-stage antibody hopeful